Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00073385 | Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer | PHASE2 | COMPLETED | 225 | — | — | Sep 1, 2003 | Oct 1, 2004 | Aug 30, 2005 | 8 | United States, India +1 |
| Name | Type | Description |
|---|---|---|
| Pivanex | DRUG | - |
| Docetaxel | DRUG | - |
Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Treatment with one prior platinum-based chemotherapy regimen (Eligible patients may include: 1. Patients previously treated with adjuvant or neoadjuvant chemotherapy (must be completed within 6 mo...